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ABSTRACT
DISCRIMINATIVE STIMULUS EFFECTS OF GABAPENTIN
By
Michael Ryan Zuidema Jr.
The present study sought to evaluate the discriminative stimulus effects of the anticonvulsant
gabapentin in rats trained to discriminate 30.0 mg/kg gabapentin from vehicle in a two-lever
drug discrimination task. All of the ten rats tested were able to establish gabapentin as an
interoceptive cue. Gabapentin produced full generalization (≥ 80% gabapentin-lever responding)
for itself at 30.0, 60.0, and 120.0 mg/kg doses. Pentobarbital produced full substitution, while
pregabalin, carbamazepine, fentanyl, and buspirone produced partial substitution (≥ 60%
gabapentin-lever responding) for gabapentin. Ethanol and raclopride did not substitute for
gabapentin. The psychostimulant amphetamine did not produce substitution; however, the 0.25
mg/kg dose of amphetamine fully substituted in five of ten rats. Based on these findings, some
depressant (i.e., pentobarbital and fentanyl), anxiolytic (i.e., buspirone), and anticonvulsant
compounds (i.e., pregabalin and carbamazepine) produce full or partial substitution to 30.0
mg/kg gabapentin. Additionally, the dopamine releaser amphetamine also produced full
substitution in half of the rats tested. Many of the compounds that produced substitution in this
study are controlled substances capable of producing rewarding subjective effects. The
substitution demonstrated in this study coincides with the past reports of poly-drug misuse,
indicating the ability of gabapentin to modulate neurotransmitter pathways involved in positive
drug effects. Thus, these modulatory effects should be considered by clinicians and researchers
when working with gabapentin.

i

Copyright by
MICHAEL RYAN ZUIDEMA JR.
© 2018

ii

TABLE OF CONTENTS

INTRODUCTION…………………………………………………………………………...……1
Gabapentin……………………………………………………………………………….3
Pharmacology…………………………………………………………………….3
Effects…………………………………………………………………….……….7
Effects of gabapentin for the treatment of epilepsy……………………..……..8
Effects of gabapentin for the treatment of neuropathy……………….……….9
Drug misuse…………………………………………………………..…………11
Drug Discrimination……………………………………………………………………12
Rationale………………………………………………………………………...………15
THESIS STATEMENT……………………………………………………………….…………20
METHODS AND MATERIALS……………………………………………………….………..21
Animals………………………………………………………………………..….……..21
Apparatus………………………………………………………………….……………21
Drugs…………………………………………………………………………………….21
Procedures………………………………………………………………...…………….22
Lever-press training………………………………………….…………………22
iii

Single-lever (errorless) training……………………………………..…………23
Two-lever discrimination training…………………………………..…………23
Generalization testing……………………………………………….………….24
Data Analysis………………………………………………………………...………….24
RESULTS………………………………………………………………………….…………….26
Gabapentin Drug Discrimination Training…………………………………..……….26
Gabapentin Time Course………………………………………………………………27
Generalization Testing…………………………………………………………...……..29
Ethanol……………………………………………………………………….………….31
Pregabalin……………………………………………………………………………….33
Carbamazepine…………………………………………………………………………35
Pentobarbital……………………………………………………………...…………….37
Fentanyl…………………………………………………………………..……………..39
Buspirone…………………………………………………………………..……………41
Amphetamine…………………………………………………………...………………43
Raclopride……………………………………………………………………………….45
DISCUSSION……………………………………………………………………………………48
Gabapentin……………………………………………………………..……………….48

iv

Ethanol…………………………………………………………………………………..49
Pregabalin………………………………………………………………………………50
Carbamazepine…………………………………………………………………………50
Pentobarbital……………………………………………………………………………51
Fentanyl…………………………………………………………………………………52
Buspirone……………………………………………………………..…………………52
Amphetamine…………………………………………………………..……………….53
Raclopride……………………………………………………………………………….54
Limitations........................................................................................................................54
Directions for Future Research……………………………………………..…………55
Conclusion………………………………………………………..……………………..55
REFERENCES…………………………………………………………………….…………….58
APPENDIX A……………………………………………………………………………………81
Order of drug testing for each animal…………………………………………..…….81
Substitution testing results for each animal………………………….……………….82
APPENDIX B……………………………………………………………………………………84
Institutional Animal Care and Use Committee approval form……………………...84

v

INTRODUCTION
Gabapentin, a GABA analog, is an anticonvulsant primarily used for the treatment of
epileptic seizures, but also other disorders, such as neuropathic pain. It is used as an off-label
(i.e., non-FDA approved uses) treatment for anxiety, insomnia, bipolar disorder, and restless leg
syndrome (Sobel, 2012, p. 124), and has been used in the treatment of opioid withdrawal,
cocaine dependency, and alcohol, benzodiazepine, and pentazocine detoxification (VictorriVigneau, Guerlais & Jolliet, 2007). Although gabapentin was initially synthesized to mimic the
neurotransmitter GABA, it does not bind with GABA receptors. Instead, the action of gabapentin
may involve interaction with voltage-gated Ca2+ channels, ultimately reducing neurotransmitter
release from affected neurons (Davies et al., 2007) and postsynaptic excitatory response. There is
also evidence to support the drug’s modulation of GABA metabolism (Schifano, 2014). Further
exploration of the pharmacological actions of gabapentin could be especially beneficial in lieu of
the relatively liberal prescription of gabapentin.
Many of the reports indicating psychoactive subjective effects from gabapentin are
relatively recent and few studies have been conducted to specifically examine these effects in a
laboratory setting. The most common and effective procedure for examining the pharmacological
actions mediating a compound’s subjective effects is drug discrimination. Drug discrimination is
an operant conditioning procedure that establishes a drug’s effects as a discriminative cue,
signaling when a behavioral response will achieve a reward. From weeks of training in this
procedure, laboratory animals (typically rats) learn to respond only when the specific cue is
present; what we find from this procedure is that responding will also occur for different
compounds, as long as the other compounds closely match the same subjective effects. The
interpretive value from testing different compounds comes from knowing the pharmacological
6

actions of these different compounds. In this way, we can deduce the pharmacological actions
likely involved in eliciting a training drug’s subjective effects.
No studies have examined the discriminative cue properties of gabapentin as a training
drug in a drug discrimination procedure. Therefore, the proposed study will train rats to
discriminate gabapentin from its vehicle (the solvent used for gabapentin, acting like a placebo)
and then test a series of compounds from different drug classes and with known pharmacological
actions. In particular, these compounds will include those with known abuse potential. The aim
of this study is to illuminate the mechanisms mediating the subjective effects of gabapentin and
the degree to which these effects are similar to those of known drugs of abuse.

7

Gabapentin
Gabapentin (Neurontin®, 1-(aminomethyl)cyclohexanacetic acid), a GABA (gammaaminobutyric acid) analog, is an anticonvulsant medication primarily used for the treatment of
epileptic seizures and neuropathic pain. It is used as an off-label (i.e., non-FDA approved uses)
for the treatment of anxiety, insomnia, bipolar disorder, and restless leg syndrome (Sobel, 2012,
p. 124), and has been used in the treatment of opioid withdrawal, cocaine dependency, and
alcohol, benzodiazepine, and pentazocine detoxification (Victorri-Vigneau, Guerlais & Jolliet,
2007).
Gabapentin is manufactured under the brand name Neurontin by Parke-Davis, a
subsidiary of Pfizer. Another subsidiary of Pfizer, Greenstone manufactures a generic version of
the drug. Gabapentin became FDA (U.S. Food and Drug Administration) approved in December
1993 for the adjunctive treatment of partial seizures (Mack, 2003). In 2000, the drug’s approval
was extended to children for the treatment of partial seizures, and in 2004 for treating
postherpetic neuralgia (complication of shingles in which pain lasts long after the condition
disappears) (Pfizer, 2011; Mack, 2003). In 2011, a prodrug form of gabapentin designed to
increase oral bioavailability (gabapentin enacarbil) was approved for the treatment of restless leg
syndrome (Landmark & Johannessen, 2008).
Pharmacology. Gabapentin is synthesized by adding a cyclohexyl group to the backbone
of GABA (Petroianu & Schmitt, 2002). The molecular weight is 171 and the pKA is 3.7. The
chemical is not fully metabolized in humans, and bioavailability of gabapentin is not
proportional to the dose administered. This means that as the dose increases (900, 1200, 2400,
3600, and 4800 mg/day given in three doses), bioavailability of the drug decreases (60%, 47%,
34%, 33%, and 27%, respectively) with food playing only a small role on absorption (Pfizer,
8

2011). Gabapentin distribution occurs through blood circulation via plasma protein binding, and
the drug is eliminated from the system as an unchanged drug through renal excretion. The halflife of gabapentin is 2 to 3 hours in rats (Radulovic et al., 1995; Vollmer & Koelle, 1986), 5 to 7
hours in humans, and is unaffected by dose or dose schedule (Pfizer, 2011).
Although gabapentin was initially synthesized to mimic the neurotransmitter GABA, it
does not bind to GABA receptors. Gabapentin is not converted into GABA, a GABA agonist
(Pfizer, 2011), nor does it inhibit GABA reuptake. Gabapentin lacks an appreciable affinity for
monoamine receptors, cholinergic receptors, excitatory amino acid receptors, and calcium
channels (Petroianu & Schmitt, 2002).
Researchers first investigated gabapentin’s interaction with the L-amino acid transport
system to identify the drug’s primary mechanism of action (Sills, 2006). Although this system is
a major Na+-independent carrier for large alpha-amino acids in mammalian cells, gabapentin, a
gamma-amino acid, is also transported via this network (Su, Lunney, Campbell & Oxender,
1995). Gabapentin is absorbed through the small intestine and transported through the bloodbrain barrier and distributed to the nervous system via this transport system (Su et al., 1995). Yet,
recent research suggests that although the L-amino acid transport system directly correlates with
both drug absorption in the gastrointestinal tract and distribution across the blood-brain barrier,
this interaction does not contribute to the drug’s clinical efficacy (Belliotti et al., 2005; Schwarz
et al., 2005).
Instead, the action of gabapentin may involve interaction with voltage-gated Ca2+
channels (Davies et al., 2007; Sills, 2006). Gee et. al. (1996) more accurately identified this
binding site to be the α2δ accessory subunit of the voltage-gated calcium channel complex.
Gabapentin binds with two of the four Ca2+ channel α2δ isoforms, α2δ-1 and α2δ-2 (Taylor,
9

2004). Knock-in of the R217A mutation of the α2δ-1 subunit results in decreased gabapentin
binding, limiting analgesic, anxiolytic, and anticonvulsant effects (Taylor, 2004). This evidence
strongly supports the action of these drugs occurring at the α2δ-1 subunit. In a study by Field,
Hughes & Singh (2000), further evidence was reported in support of the mediation of gabapentin
on α2δ accessory subunits. 3-methyl gabapentin (binds to α2δ accessory subunit with high
affinity, KD = 38 nM) was found to dose-dependently block the effects of static and dynamic
allodynia in two rat models of pain (Field, Hughes & Singh, 2000; Suman-Chauhan, Webdale,
Hill & Woodruff, 1993), further implicating the α2δ accessory subunit in gabapentin’s
mechanism in pain models. A more recent study by Brown and Randall (2005) concluded that
gabapentin acts to selectively block calcium channels containing the α2δ-1 subunit, rather than
inhibiting the α2δ-1 receptor. This α2δ-1 subunit blockage is currently thought to be the primary
pharmacological mechanism behind the action of gabapentin.
Evidence also exists to suggest the drug’s modulation of GABA metabolism (Leach et
al., 1997; Schifano, 2014) synthesis (Taylor, Vartanian, Andruszkiewicz & Silverman, 1992),
and non-vesicular release of GABA (Gotz, Feuerstein, Lais & Meyer, 1993; Honmou, Kocsis &
Richerson, 1995). Due to the drug’s structural similarities with baclofen, a GABAB receptor
agonist, Ng et. al. (2001) suggests that gabapentin may act similarly as a postsynaptic GABAB
agonist to select receptor subtypes in the hippocampus. However, because the co-administration
of GABAB antagonists have not been shown to reverse the antihyperalgesic effects of
gabapentin, other mechanisms are thought to more likely mediate the drug’s effects (Patel et. al.,
2001). While gabapentin has been shown to increase overall GABA levels in neocortical ex vivo
analysis (Errante, Williamson, Spencer & Petroff, 2002) and in vivo nuclear magnetic resonance
spectroscopy of the occipital cortex (Errante et al., 2002; Petroff, Rothman, Behar, Lamoureux &
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Mattson, 1996), these findings have not been replicable in other studies measuring GABA
concentrations in rodent brains (Leach et al., 1997; Errante & Petroff, 2003).
Some studies suggest that gabapentin is able to produce a delayed allosteric enhancement
of voltage gated K+ channels in rat dorsal root ganglions, possibly through protein kinase A
activation (McClelland, Evans, Barkworth, Martin & Scott, 2004). Although the drug has been
shown to modulate ATP-sensitive K+ channels in human neocortical and rat hippocampal slices
(Freiman et al., 2001), this effect has not been able to be replicated in other models such as the
rat dorsal root ganglion (Sarantopoulos, 2003).
Because gabapentin contains anticonvulsant properties, neuronal voltage-gated Na+
channels have been investigated to evaluate the drug’s ability to block repetitive firing. Although
moderate inhibitory effects can be elicited with drug exposure, research suggests that the effect
of gabapentin is mediated by yet another unidentified mechanism rather than through blockades
of voltage-gated Na+ channels (Sills, 2006). For example, gabapentin fails to inhibit
batrachotoxin, a Na+ channel-specific agent shown to induce depolarization in vesicular
preparation (Creveling, McNeal, Daly & Brown, 1983), rat neocortical membranes (Dooley,
Donovan, Meder & Whetzel, 2002), Na+ currents in Chinese hamster ovary cells (Xie et al.,
2001), or Ca2+ influx in rat cortical synaptosomes (Meder & Dooley, 2000).
Based on the findings discussed above, a single common mechanism is thought to be
most prominent in gabapentin’s mechanism of action. Gabapentin most likely predominantly
works to inhibit voltage gated calcium channels via the α2δ subunit, ultimately reducing
neurotransmitter release and postsynaptic excitability (Sills, 2006). Because of the presynaptic
nature of gabapentin’s proposed mechanism, it is not unreasonable to theorize that this accounts
for other effects of the drug, including GABAB receptor activation, presynaptic NMDA receptor
11

modulation, and the overall decrease of neurotransmitter release (Sills, 2006). Further
investigation is required to determine whether calcium channel interaction alone is able to
explain the broad clinical spectrum of gabapentin.
Effects. Gabapentin is commonly thought to exhibit few cognitive and
neuropsychological side effects at therapeutic doses (Loring, Marino & Meador, 2007). Many
studies suggest even at relatively high doses, gabapentin demonstrates a favorable CNS-related
profile (Chadwick et al., 1998). For example, single-dose administration of gabapentin in
humans was associated with improved concentration and EEG slowing (Saletu et al., 1986). In
long-term administration, gabapentin scored better on 8 of 31 neuropsychological measures
compared to carbamazepine, only scoring lower than placebo on four measures (Meador et al.,
1999). However, although well tolerated cognitively, gabapentin does seem to pose certain risks
to neuropsychological function (Loring, Marino & Meador, 2007).
As prescribing rates of gabapentin have increased, so too have reports of drug misuse and
overdose fatalities. Recent data indicate that gabapentin is abused across a wide range of doses
including therapeutic (900-3600 mg/day) and supratherapeutic doses (3-20 times greater than
clinically advisable doses) (Smith, Havens & Walsh, 2016; Schifano, 2014). Individuals who
possess a prescription for gabapentin and abuse the drug often take doses much higher than the
amount prescribed, while, in contrast, those who abuse the drug without a prescription are more
likely to take doses within clinical guidelines (Wilens, Zulauf, Ryland, Carrellas & CatalinaWellington, 2014; Smith, Lofwall & Havens, 2015). Use of these high amounts suggest the
development of tolerance, one of many indicators of substance dependence.
Clinicians have begun noting patients’ histories that may account for unexpected effects
from gabapentin. According to Smith, Higgins, Baldacchino, Kidd & Bannister (2012), for
12

example, “effects vary with the user, dosage, past experience, psychiatric history, and
expectations.” Reports reveal that gabapentin may elicit an array of subjective effects
reminiscent of opioids, benzodiazepines, and psychedelics (Smith, Havens & Walsh, 2016). Case
studies report that gabapentin alone (1500-12,000 mg doses) and in combination with other drugs
(such as buprenorphine, naloxone, methadone, baclofen, quetiapine, and alcohol) can elicit a
type of euphoria similar opioid-induced euphoria (Reeves & Burke, 2014; Reeves & Ladner,
2014; Fischer, Ban, Rogers, Fischer & Trudeau, 1994; Baird, Fox & Colvin, 2014; Smith et al.,
2012; Schifano et al., 2011). In another case study, individuals experienced a cocaine-like high
after snorting powder from gabapentin capsule medication (Reccoppa, Malcolm & Ware, 2004).
More commonly reported psychoactive effects of gabapentin include sedation, relaxation, and
calmness, sometimes in combination with other drugs such as quetiapine, alcohol, cannabis, or
buprenorphine (Pittenger & Desan, 2007; Markowitz, Finkenbine, Myrick, King & Carson,
1997; Reeves & Burke, 2014; Reeves & Ladner, 2014; Schifano et al., 2011). Other effects
shown consist of an improved sociability, a marijuana-like high (Smith et al., 2012), cocaine-like
high (Reccoppa, Malcolm & Ware, 2004), 3,4-methylenediocy-mehtamphetamine (MDMA)-like
high, ‘amphetamine rush’, dissociative effects (Schifano et al., 2011), increased focus and
energy, improved sleep (Satish, Kandasamy, Jayarajan & Benegal, 2015), and becoming more
talkative (Schifano et al., 2011).
Effects of gabapentin for the treatment of epilepsy. Epilepsy is a disease of the central
nervous system in which nerve cell activity becomes disrupted (Meyer, Dua, Ma, Saxena &
Birbeck, 2010). This disruption of nerve activity can cause seizures (often characterized by
involuntary jerking movements of the arms and legs), abnormal behavior, temporary confusion,
and loss of consciousness or awareness (Mayo Clinic Staff Print, 2015). Genetic influence is
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likely to play a role in many cases of idiopathic epilepsy (Pandolfo, 2011), and the majority of
genes associated with epilepsy represent subunits of receptor channels that mediate sodium,
potassium, calcium, and GABA neurotransmission (Rees, 2010).
Sodium channels are one of the primary targets amongst traditional antiepileptic
medications. For example, anticonvulsant medications such as lamotrigine, topiramate, and
zonisamide all modulate Na+ channels (Leach, Marden & Miller, 1986; Loring, Marino &
Meador, 2007). Although, as noted previously, evidence would suggest gabapentin’s action to be
mediated by mechanisms other than interaction with Na+ channels, gabapentin does act on other
similar mechanisms seen in typical anticonvulsants. In addition to Na+ channel interaction,
lamotrigine works by glutamate reduction (Leach, Marden & Miller, 1986), topiramate by
GABA potentiation and glutamate antagonism, zonisamide by blocking presynaptic Ca2+
channels, and tiagabine by inhibiting GABA reuptake (Loring, Marino & Meador, 2007).
Effects of gabapentin for the treatment of neuropathy. Peripheral neuropathy is a
disease or damage to the peripheral nervous system (National Institute of Neurological Disorders
and Stroke, n.d.). Affected areas can become hypersensitive to stimuli, resulting in the perception
of pain from stimuli that do not normally evoke pain. In severe cases, symptoms may worsen to
burning pain, paralysis, muscle atrophy, and organ dysfunction. Nerve damage to organs
responsible for vital functions may result in failure or functional impairment in the form of
sweating, digestive complications, sexual dysfunction, and difficulty breathing (National
Institute of Neurological Disorders and Stroke, n.d.).
Medications used to treat peripheral neuropathy generally act on the central nervous
system and include antidepressants, anticonvulsants and narcotics. Tricyclic antidepressants (e.g.
amitriptyline) and serotonin-norepinephrine reuptake inhibitors (SNRI) (e.g. duloxetine
14

hydrochloride) require chronic treatment and are thought to exert their effects through
noradrenergic descending pathways and the recruitment of noradrenaline via sympathetic fibers
(Kremer, Salvat, Muller, Yalcin & Barrot, 2016). These compounds seem to target both α2 and
β2 adrenoreceptors and require μ and  opioid receptor interaction to produce therapeutic action
(Kremer et al., 2016). Although tricyclic antidepressants provide effective pain relief, adverse
effects are often seen such as arrhythmia, sedation, dry mouth, constipation and urinary retention
(Rowbotham et. al., 1998).
In animal models, gabapentin has been shown to decrease allodynia induced by lesions
(Chen, Eisenach, McCaslin, & Pan, 2000; Field, Gonzalez, Tallarida, & Singh, 2002; Miranda et
al., 2015). Although the mechanism of action remains unclear, gabapentin may exert its
antiallodynic effects by binding to the α2δ-1 subunit of voltage-gated Ca2+ channels, decreasing
excitatory neurotransmitter release. Additionally, gabapentin has been shown to activate NOcyclic GMP-ATP sensitive K+ channel pathways (Ortiz, Medina-Tato, Sarmiento-Heredia,
Palma-Martinez, & Granados-Soto, 2006; Godinez-Chaparro, Quinonez-Bastidas, RojasHernandez, Austrich-Olivares, Mata-Bermudez, 2017), non-competitvely inhibit NMDA
receptors (Hara & Sata, 2007), and activate descending noradrenergic pain inhibitory system via
α2 adrenoreceptors, which explains the drug’s antinociceptive effects (Kremer et al., 2016).
Gabapentin is a single nonopioid medication that provides safety and pain relief to
postherpetic neuralgia patients, making it a strong candidate for treatment. In a multicenter,
randomized, double-blind, placebo-controlled, parallel design, 8-week trial conducted by
Rowbotham et. al. (1998), 229 subjects were used to determine the efficacy and safety of
gabapentin in reducing postherpetic neuralgia pain. Over a 4-week period, gabapentin was
titrated up to a maximum dose of 3600 mg/d in the experimental group, followed by 4 weeks at
15

the maximum tolerated dose (Rowbotham et. al., 1998). Efficacy was measured based on an 11point Likert scale rating average daily pain (0, no pain; 10, worst pain) from the baseline week
until the final week of therapy (Rowbotham et. al., 1998). Patients receiving gabapentin had
significantly lower daily pain scores (6.3 to 4.2) compared with change in subjects that received
placebo (p < 0.001) (Rowbotham et. al., 1998), demonstrating that gabapentin is an effective
treatment of pain associated with postherpetic neuralgia.
More recently, a double-blind, randomized, placebo-controlled 8-week study was
conducted by Serpell & Neuropathic Pain Study Group (2002) in order to determine the efficacy
and safety of gabapentin in neuropathic pain. Patients exhibited a range of symptoms, including
allodynia, burning pain, shooting pain or hyperalgesia (Serpell & Neuropathic Pain Study Group,
2002). In the experimental group, gabapentin was titrated up to 900 mg/d over 3 days, and
ultimately up to 2400 mg/d by the end of week 5 (Serpell & Neuropathic Pain Study Group,
2002). Efficacy was measured using an average daily pain score. In patients receiving gabapentin
treatment, average daily pain scores significantly decreased by 21% (p < 0.05) (Serpell &
Neuropathic Pain Study Group, 2002), demonstrating that gabapentin is effective is reducing
pain-like symptoms in patients with neuropathic pain symptoms.
Drug misuse. Gabapentin is currently labeled an uncontrolled substance lacking abuse
potential, and thus, is widely prescribed as an off-label medication. However, there have been
many documented cases of gabapentin misuse, abuse, dependence, and withdrawal. Accordingly,
evidence suggests that the drug may exert reinforcing effects that are dissociable from its
anticonvulsant effects (Bossert & Franklin, 2003). A recent meta-analysis by Smith, Havens, &
Walsh (2016) reported gabapentin misuse to be prevalent in 1% of the general population. Of
this one percent, 40-65% misuse gabapentin in conjunction with other prescription medications,
16

and 15-22% misuse gabapentin specifically with opioids (Smith, Havens, & Walsh, 2016).
Motives behind gabapentin abuse were identified as: recreational use, control of mood/anxiety,
pain relief, reduced cravings from other drugs, substitution for other drugs, potentiating effects of
drug abuse treatment, addiction to gabapentin, and intentional self-harm (Smith, Havens, &
Walsh, 2016).
As previously stated, users report subjective effects reminiscent of opioids,
benzodiazepines, and psychedelics. These subjective effects were reported over a range of doses,
including clinically therapeutic doses (Smith, Havens, & Walsh, 2016). In addition to these drug
effects, evidence suggests that gabapentin may be abused in conjunction with other drugs,
possibly providing potentiating or modulatory drug effects. Accordingly, gabapentin is reported
to be most commonly abused with prescription opioids (Smith et al., 2012; Smith, Lofwall, &
Havens, 2015), benzodiazepines (Smith, Lofwall, & Havens, 2015; Peterson, 2009), and alcohol
(Schifano et al., 2011); although, reports exist of conjunctive use with cannabis, selective
serotonin reuptake inhibitors, lysergic acid diethylamide (LSD), gamma-hydroxybutyric acid
(GHB), and amphetamine (Schifano et al., 2011).
Drug Discrimination
Drug discrimination (DD) is an operant conditioning procedure that establishes a drug’s
effects as a discriminative cue. The subjective effects of the drug act to signal when a laboratory
animal’s response (e.g., lever-pressing behavior) will achieve a reward (e.g., food, water, etc.). In
both human and non-human DD models, the subject must perform a response or behavior that
distinguishes drug and nondrug conditions (Buccafusco, 2009). When applied in non-human
models, subjects are trained to discriminate between a drug and vehicle (often 0.9% sodium
chloride solution that is also the solvent for the drug) by pressing the drug-appropriate lever in an
17

operant chamber to receive reinforcement. The established distinction between drug and nondrug
conditions allows an experimenter to deduce that the drug has been perceived and investigate the
stimulus effects of the drug being studied (Buccafusco, 2009). Drug discrimination provides a
powerful tool to studying in vivo drug properties, and can be used accordingly to study nontraining drugs for similar actions. Thus, drug discrimination provides a model for screening
novel drugs that are able to be established as a discriminative cue. The specificity of a
discriminative stimulus for certain CNS receptors can be demonstrated by stimulus
generalization to receptor-selective compounds.
One study sought to assess the discriminative properties of tiagabine, a drug which exerts
its anticonvulsant and sleep-enhancing effects by inhibiting reuptake at the GABA transporter
(GAT-1). Using 30.0 mg/kg tiagabine-trained rats, McDonald et al. (2008) reported no stimulus
generalization to gabapentin, which has also been thought to inhibit GABA GAT-1 (Loscher,
Honack, & Taylor, 1991; Sills, 2006; Goldlust, Su, Welty, Taylor, & Oxender, 1995; Leach et
al., 1997). Moreover, tiagabine also produced no generalization for zolpidem and zopiclone
(GABAA agonists). Full substitution was defined as ≥ 80% condition-appropriate responding,
and partial substitution was defined as a statistically significant (p < 0.05) increase in
generalization compared to vehicle (while not approaching full substitution, i.e., < 80%
condition-appropriate responding).
While no studies have utilized gabapentin as the training drug in a drug discrimination
procedure, studies have evaluated the stimulus effects of gabapentin as a substitute for other
training drugs. McDonald et al. (2008) trained rats to discriminate the anticonvulsant drug
tiagabine from vehicle in a two-lever drug discrimination task and evaluated drugs that may bind
to GABA receptors. Gabapentin (30.0 – 300.0 mg/kg, po) did not fully substitute for tiagabine,
18

engendering up to 40% tiagabine-appropriate responding. The only drug that fully substituted for
tiagabine was the GABAA receptor agonist gaboxadol, although this result could only be shown
in three rats due to rate suppression. In addition, the discriminative stimulus effects of tiagabine
were partially blocked by the GABAA receptor antagonist bicuculline. Based on these findings,
the discriminative stimulus effects of tiagabine appear to be mediated, at least in part, by the
activation of GABAA receptors. Further, these findings suggest that the stimulus effects elicited
by gabapentin are likely not mediated by GABAA receptor agonism, which is consistent with
pharmacological results noted earlier.
Other studies have compared the discriminative stimulus effects of cannabinoids to those
of gabapentin in order to better understand the drug’s mechanism of action. In a study by Lile,
Wesley, Michael, Thomas & Lon (2016), eight cannabis users were trained to discriminate 30
mg of the CB1/2 receptor partial agonist Δ9-THC from placebo, and then received gabapentin
(600, 1200 mg), Δ9-THC (5, 15, and 30 mg), and placebo both in combination and alone as test
compounds for substitution testing. Both doses of gabapentin alone fully substituted for the
discriminative stimulus effects of Δ9-THC and the combination of gabapentin with Δ9-THC
shifted the dose response for Δ9-THC to the left (Lile et al., 2016). In addition, it is noted that
CB1 receptor agonists act as L-voltage gated Ca2+ channel blockers (Ross, Napier & Connor,
2008; Lozovaya, Min, Tsintsadze & Burnashev, 2009), and therefore Δ9-THC-like discriminative
stimulus effects may result from the blocking mechanisms of gabapentin and Δ9-THC at Lvoltage gated Ca2+ channels (Stefani, Spadoni & Bernardi, 1998; Fink et al., 2002).
One study attempted to characterize the effects of gabapentin compared to the
discriminative stimulus effects of alcohol (1 g/kg) in rats (Besheer, Frisbee, Randall, Jaramillo &
Masciello, 2016). Gabapentin (120 mg/kg) produced partial substitution (>40% alcohol-lever
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responding) for alcohol. The study also examined the effects of gabapentin on alcohol selfadministration in rats. Gabapentin (30 and 120 mg/kg) pre-treatment resulted in increased
alcohol self-administration (Besheer et al., 2016).
Several studies have investigated gabapentin’s effects on the discriminative stimulus
properties of cocaine in rats and humans (Filip et al., 2007; Haney, Hart, Collins & Foltin, 2005;
Hart, Ward, Collins, Haney & Foltin, 2004). Filip et al. (2007) trained rats to discriminate
cocaine (10 mg/kg) from vehicle. Gabapentin (10 – 30 mg/kg) failed to block the discriminative
stimulus effects of cocaine. In this same study, gabapentin did not attenuate cocaine selfadministration responding or affect cocaine-induced reinstatement (Filip et al., 2007). Haney et
al. (2005) trained cocaine-dependent human volunteers to discriminative the stimulus effects of
cocaine from placebo. Following training, participants were assigned a chronic treatment dose of
gabapentin (0, 600 or 1200 mg/day) and then later, cocaine was tested for substitution during
gabapentin maintenance. Percent cocaine responding was significantly decreased compared to
those given gabapentin placebo. The 1,200 mg/day gabapentin also significantly decreased
“Good Drug Effect” and “Craving or I want cocaine” subjective ratings following cocaine
administration. In another study in humans, gabapentin (2,400 and 3,200 mg/day) did not
attenuate cocaine-appropriate responding. Further investigation of varying doses and
maintenance periods of both gabapentin and cocaine is warranted, considered both compounds
are commonly abused at relatively high doses.
Rationale
In order to evaluate the effects gabapentin, rats were trained to discriminate 30.0 mg/kg
gabapentin from vehicle in a two-lever drug discrimination task. The first goal of this
investigation was to determine if, in fact, gabapentin could be established as a discriminative cue
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in rats. Next, in order to elucidate the pharmacological mechanisms and stimulus properties of
gabapentin, compounds from various drug classes (i.e., selective for different receptors; e.g.,
dopamine, serotonin, GABA, etc.) were tested for stimulus generalization in these animals
(ethanol, pregabalin, carbamazepine, pentobarbital, fentanyl, buspirone, amphetamine, and
raclopride). A description of these compounds is provided below.
Ethanol produces dose-dependent effects, generally yielding depressant physiological and
psychology effects at higher doses and excitatory effects at lower doses (Prus, 2014). Ethanol has
been shown to produce its reinforcing effects through GABAA agonism, ultimately facilitating
action in the nucleus accumbens (Harris, Mihic, Brozowski, Hadingham, & Whiting, 1997;
Yoshimoto, McBride, Lumeng, & Li, 1992). Additionally, ethanol has been shown to inhibit
NMDA receptors (Krystal, Petrakis, Mason, Trevisan, & D’Souza, 2003), inhibit L-type voltagegated Ca2+ channels (Walter & Messing, 1999), increase serotonin in the nucleus accumbens
(Yoshimoto et al., 1992), and interact with endocannabinoid systems (Hungund, Szakall, Adam,
Basavarajappa, & Vadasz, 2003).
Pregabalin, a gabapentinoid compound structurally, behaviorally, and pharmacologically
similar to gabaepentin, demonstrates efficacy in the treatment of seizure and neuropathic pain.
Additionally, pregabalin is able to produce benzodiazepine-like anxiolytic effects, which
attenuate both psychic and somatic symptoms of anxiety (Kavoussi, 2006). Pregabalin shares a
novel mechanism of action with gabapentin, binding selectively to the α2δ subunit of voltagegated Ca2+ channels, ultimately reducing excitatory neurotransmitter release. Coinciding with
pregabalin’s higher binding affinity (relative to gabapentin) to the α2δ subunit, pregabalin is
considered to be more addictive, as demonstrated by the drug’s behavioral dependence
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symptoms (Bonnet & Scherbaum, 2017). Pregabalin is expected to generalize to the 30.0 mg/kg
gabapentin training dose at lower of doses of pregabalin (relative to gabapentin).
Carbamazepine is an anticonvulsant compound which exerts its effect through the
blockade of Na+ channels (Rogawski, Loescher, & Rho, 2016; MacDonald, 1995; Czapinski,
Blaszczyk, & Czuczwar, 2005), Nav1.8-like sodium channels (Cardenas, Cardenas, de Armendi,
& Scroggs, 2006) and by inhibiting serotonin reuptake (Southam, Kirkby, Higgins, & Hagan,
1998; Dailey, Reith, Yan, Li, & Jobe, 1997; Kawata et al., 2001). Although gabapentin does not
modulate serotonin reuptake or concentration (Southam et al., 1998), previous studies have
shown gabapentin and carbamazepine to share a similar profile, both producing significant
antihyperalgesic and anti-allodynic effects within a similar dose range (De Vry, Kuhl, FrankenKunkel, & Eckel, 2004; Bennet & Xie, 1988; Hunter et al., 1997; Koch, Faurot, McGuirk,
Clarke, & Hunter, 1996). Additionally, these drugs have also been evaluated for their ability to
attenuate the positive subjective effects of cocaine in rats and humans (Carroll, Lac, Asencio,
Halikas, & Kragh, 1990; Hart et al., 2004; Haney, Hart, Collins, & Foltin, 2005; Sharpe, Jaffe, &
Katz, 1992; Halikas, Crosby, Pearson, & Graves, 1997).
Pentobarbital is a highly effective anticonvulsant and sedative (Raines et al., 1979) that
exerts its effects through GABAA agonism (Leeb-Lundberg, Snowman, & Olsen, 1980),
diminishing glutamate responses (Macdonald & Barker, 1978), and by inhibiting voltage-gated
sodium (Lingamaneni & Hemmings, 2003; Wartenberg, Wartenberg, & Urban, 2001) and
calcium channels (Werz & Macdonald, 1982; Barker & Rogawski, 1993; Schoeber, Sokolova, &
Gingrich, 2010). Studies have shown that pentobarbital produces no substitution in rats trained to
discriminate 1.5 g/kg ethanol from vehicle (De Vry & Slangen, 1986) and is readily
discriminated from ethanol in a drug vs. drug discrimination task (Overton, 1977). These
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findings imply that pentobarbital produces discernably different subjective effects from ethanol
(a test compound used in this study). In rhesus monkeys trained to discriminate amphetamine
from vehicle using a signaled shock-avoidance procedure, pentobarbital produced no
substitution, further indicating pharmacological specificity (de la Garza & Johanson, 1987).
The synthetic opioid fentanyl exerts its drug effects through the agonism of μ opioid
receptors. Zhang, Walker, Sutherland, & Young (2000) showed that fentanyl has high efficacy
and specificity for the μ opioid receptor, producing similar qualitative effects at both low and
high doses. When established as a discriminative stimulus, fentanyl (0.01 mg/kg and 0.04 mg/kg)
has been shown to fully substitute for other potent μ opioid agonists (etonitazene, methadone,
and morphine) but not for spiradoline (κ opioid agonist) or amphetamine (dopamine releaser)
(Zhang et al., 2000). In another study, phencyclidine (PCP), ketamine, and (+/- )-5-methyl10,11-dihydroxy-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801) produced partial
substitution for fentanyl (0.04 mg/kg) (Koek, Colpaert, & Vignon, 1993). In both of the previous
studies, naltrexone antagonized the discriminative effect produced by fentanyl.
Buspirone, a serotonin 5-HT1A receptor agonist, dose-dependently decreases serotonin
levels, while increasing dopamine and norepinephrine levels in the brain (Loane & Politis, 2012).
Studies have demonstrated efficacy for the use of 5-HT1A agonists in treatment of neuropathic
pain in rodent models (Colpaert, 2006). Several studies investigating the discriminative stimulus
effects of buspirone in a drug discrimination procedure have found evidence in support of
buspirone’s serotonin-mediated effects (Hendry, Balster, & Rosecrans, 1983; Ator, 1991;
Mansbach & Barrett, 1987). However, there is also evidence that serotonergic receptors do not
play an important role in the drug’s effects (Davis, Cassella, & Kehne, 1988), but rather
antagonism at the dopamine D2 receptor (Kamien & Woolverton, 1990).
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The psychostimulant and rate-stabilizing agent amphetamine produces dose-dependent
effects. At low doses, amphetamine typically produces positive subjective effects and
characteristic stimulant-like effects (i.e., increased alertness, energy, sense of well-being) (Smith
& Davis, 1977), while higher doses are capable of producing euphoria (Prus, 2014).
Amphetamine’s rate-dependent effects are contingent on predrug administration response rates
(Ginsburg, Pinkston, & Lamb, 2011), making the drug useful in the treatment of ADHD.
Amphetamine exerts its effects by promoting monoamine (i.e., dopamine, serotonin,
norepinephrine) efflux. In vitro, amphetamine has been shown to stimulate monoamine release,
as well as inhibit reuptake (Heal et al., 1988). Seidel et al. (2005) more accurately described
amphetamine’s monoamine-releasing effect to be mediated through the reversal of monoamine
transporter proteins and by displacing vesicular monoamines.
The synthetic compound raclopride exerts its effects through antagonism of the dopamine
D2 receptor. Raclopride possesses a high specificity and affinity (KD = 1.2 nM in the rat striatum)
for the dopamine D2 receptor, and thus, is a useful tool for assessing D2 receptor activity in
studies investigating pharmacological action of compounds (Kohler, Hall, Ogren, & Gawell,
1985). Raclopride has not been shown to produce substitution in drug discrimination paradigms
that use a non-dopaminergic modulating compound as a discriminative cue. Based on these
findings, raclopride was not expected to substitute for the anticonvulsant gabapentin.
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THESIS STATEMENT
Understanding drugs’ specific subjective effects and pharmacological actions is
imperative to understand the pharmacological effects of compounds used in humans, including
the risks that a drug may have abuse potential. Gabapentin is a GABA analogue compound
approved for the treatment of epilepsy and neuropathy, but used off-label for treating a number
of disorders, such as insomnia, bipolar disorder, and anxiety. Some reports indicate that
gabapentin also has abuse potential. There is relatively little known about the behavioral
pharmacological effects of gabapentin.
Drug discrimination procedures, which evaluate the subjective effects of drugs and link
these effects to pharmacological mechanisms of action, have not yet been conducted as a means
to carefully examine the discriminative stimulus effects of gabapentin. Studies using gabapentin
as a test compound have reported partial substitution for Δ9-THC and for alcohol, but no
substitution for anticonvulsant drugs mediated by GABAA receptors. Moreover, gabapentin has
not been shown to block the discriminative stimulus effects of cocaine in rats, but it has
attenuated the discriminative stimulus effects of cocaine in humans. Yet, gabapentin is used for
the treatment of alcohol withdrawal and has been shown to reduce the positive subjective effects
produced by cocaine. This study aims to evaluate gabapentin as the training drug in a drug
discrimination procedure, which will serve to examine the pharmacological mechanisms that
mediate this compounds subjective effects.
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MATERIALS AND METHODS
Animals
Ten male Sprague Dawley rats (Charles River Laboratories, Portage, MI) were housed
individually under 12-hour light/dark (6 am/6 pm) conditions with regulated temperature and
humidity. Rats were trained to discriminate 30.0 mg/kg gabapentin from vehicle. Free feed
weights for each rat were collected, then home cage food rations were restricted to achieve 90%
of free-feeding weights (M = 370.83 +/- 4.35g). Water was available ad lib. Rats were fed
immediately after daily training or testing sessions, occurring at approximately the same time
each day.
Apparatus
Five standard rat operant chambers (ENV-008-VP, MED Associates, St. Albans, VT)
contained in sound-attenuating cabinets were used in the drug discrimination study (ENV018MD, MED Associates, St. Albans, VT). Cabinets were equipped with fans for masking noise
and ventilation, and all equipment was controlled by MED-PC IV software. The operant
chambers (30-cm L × 24-cm W × 29-cm H) were constructed of a Plexiglas top and side door
panels, with other walls and components made of stainless steel. A concealed light bulb located
near the top of the operant chamber provided illumination during all training and test sessions.
Two retractable levers (gabapentin and vehicle levers) were located on either side of a food
hopper centered on the stainless steel wall of the chamber. Food reinforcers consisted of 45-mg
food pellets (Dustless Precision Pellets, Rodent Grain-Based Diet, Bio-Serv, Flemington, NJ).
Drugs
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Generalization testing was conducted with the gabapentin, (Neurontin®), amphetamine
(Adderall®), raclopride, pentobarbital (Nembutal®), buspirone (Buspar®), ethanol, fentanyl
(Sublimaze®), carbamazepine (Tegretol®), and pregabalin (Lyrica®). All drugs were purchased
from Sigma-Aldrich, St. Louis, MO, and all drugs, with the exception of carbamazepine, were
dissolved in 0.9% saline solution. Carbamazepine was dissolved in β-cyclodextrin. Vehicle for
all drugs consisted of 0.9% saline solution. All drugs were administered intraperitoneally (ip) at a
volume of 1 ml/kg body weight, except for ethanol, which was administered intragastrically via
oral gavage. All drugs were administered 30 minutes prior to test sessions. Injection times were
based on cumulative dosing procedure (Wenger, 1980), and all doses were chosen based on
previous published literature to determine a sufficient dose of a compound that produces a
cessation of responding (Pfizer, 2011).
Procedures
Training procedures described below are for rats trained to discriminate 30.0 mg/kg
gabapentin from vehicle. For all of the following procedures, no more than one session was
conducted per day. Training sessions consisted of no more than one trial (i.e., each rat received
one injection and underwent training procedures) per day, whereas test sessions consisted of
multiple trials (one trial for each level of cumulatively dosed test compound, including vehicle [0
mg/kg test compound]).
Lever-press training. After one magazine training session, in which no levers were
available and food pellets (45mg dustless grain pellet) (Bio-Serv, Flemington, NJ) were
delivered every 60 seconds (fixed time 60 sec), lever press training sessions began. During lever
press training, only the center lever was available in the chamber (other two levers were
retracted) and every lever press resulted in the delivery of one food pellet (i.e., a fixed ratio [FR]
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1). The center lever was chosen to prevent biased responding, due to either the left or the right
lever eventually being paired with the training drug’s vehicle. A session ended when either 30
food pellets were delivered or 15 minutes’ time had elapsed. As the rats acquired the lever-press
response, the FR requirement was gradually increased until FR 30 responding occurred reliably.
Single-lever (errorless) training. During single-lever (errorless) training sessions, rats
were administered either the training drug (i.e., gabapentin, 30.0 mg/kg dose) or vehicle (0.9%
physiological saline, Sigma-Aldrich, St. Louis, MO) 60 minutes prior to a training session (later
shortened to 30 minutes due to cumulative dosing procedure). For each rat, one lever (left or
right) was extended for drug-treatment sessions and the other lever was extended for vehicletreatment sessions. Drug and vehicle lever assignments were counterbalanced between subjects
to account for olfactory cues (Extance and Goudie, 1981). Four sessions of each condition were
conducted in a single/double alternation design for gabapentin (G) and the discriminate vehicle
saline (S) for training sessions (i.e., GSGGSSGS). Animals were required to maintain FR 30
responding and successfully obtain 30 food pellets within each session for seven of eight
consecutive training sessions before two-lever discrimination training began.
Two-lever discrimination training. During the two-lever sessions, both levers were
extended in the operant chamber. Discrimination training sessions continued to follow a
single/double alternation design. During these sessions, a resetting counter was used for FR
responding (e.g., if a rat pressds the incorrect lever before 30 responses on the conditionappropriate lever, FR response requirement was reset to 0, and the next food pellet will require
thirty consecutive presses on the condition-appropriate lever). In order to complete two-lever
training, the rats had to meet the following criteria for five of six consecutive sessions: (1) the
first completed FR 30 requirement must have been on the condition-appropriate lever, (2)
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cumulative response rates of no less than 5 RPM, (3) at least 80% condition appropriate
responding prior to the first fixed ratio, and (4) at least 80% cumulative condition-appropriate
responding over the entire session. These sessions continued throughout the study to ensure
discriminative accuracy was maintained.
Generalization testing. Prior to a test sessions, rats were required to successfully
complete a minimum of two discrimination training sessions (i.e., all four training criteria had to
be met during the training sessions immediately preceding the test session). Test sessions were
the same as two-lever training sessions except that no reinforcers were delivered during the test
session, and 30 consecutive responses on either single lever resulted in the session ending and a
single food pellet to be delivered 2 seconds later. Control tests with the drug vehicle were
conducted prior to testing each test compound. Cumulative dosing techniques were used for each
test compound, in which supplemental doses were administered in addition to previous treatment
in order to reach the desired effective dose (e.g., if the low dose were 1.0 mg/kg and the next
dose were 5.0 mg/kg, then the next amount given of the drug would be 4.0 mg/kg) (Wenger,
1980). Drugs were tested in a pseudo-random order (see Appendix A). All training sessions were
15 minutes long, and test sessions lasted until an FR 30 schedule had been completed on a single
lever or 15 minutes’ time had elapsed.
Data Analysis
Percent lever responding for drug and non-drug levers, responses per minute (RPM), and
the lever on which the first FR 30 schedule was completed were collected for each training and
test session. Percent gabapentin-appropriate responding and RPM were reported as means (+/the standard error of the mean [SEM]) in dose-effect curves. Full-substitution was defined as
80% or greater gabapentin-appropriate responding, and partial substitution was defined as 60%
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or greater and less than 80% gabapentin-appropriate responding. Because these procedures were
designed to evaluate test compounds for gabapentin-like stimulus effects, criterion-based
assessment (i.e., full, partial, or no substitution), rather than statistical assessment, will be used
for percent gabapentin-appropriate responding results. This method of analysis is standard for
drug discrimination research (Glennon & Young, 2011). For drugs that produced full substitution
(i.e., ≥ 80% gabapentin-appropriate responding), ED50 values were obtained for the dose–
response curves (with 95% conﬁdence levels) using a least-squares linear regression analysis
(Goldstein, 1964). If an animal’s response rate falls below 5 RPM, its percent lever-responding
data was included in either the dose–effect curve or the ED50 calculations. A one-factor repeatedmeasures analysis of variance (ANOVA) was conducted to assess changes in response rates.
When appropriate, Dunnett’s multiple comparison tests were conducted to identify signiﬁcant
changes in response rates for drug doses relative to vehicle.
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RESULTS
Gabapentin Drug Discrimination Training
Of the initial 10 animals obtained for this study, all 10 of these subjects met the training
criteria. Discrimination training and subsequent time course analysis were initially conducted 60
minutes after drug administration. However, this was later reduced to 30 minutes based on
cumulative dosing procedure, post-injection times found in a previous study (Pan, Eisenach, &
Chen, 1999), and empirical time course analysis data (i.e., full substitution produced in the 30.0
mg/kg training dose 30 minutes post drug administration). These 10 subjects met the two-lever
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discrimination criteria after a mean of 40.8 (+/- SEM = 3.38) sessions (Figure 1).

3 0 .0

m g /k g

G a b a p e n tin

(N = 1 0 )
(2 )
(7 )

1 0 0
(4 )

(6 )

(1 )

(3 )

8 0

6 0

4 0
3 0 .0

m g /k g

G a b a p e n t in

V e h ic le

2 0

0
5

1 0

1 5

S e s s io n s

2 0

2 5

3 0

(2 X )

Fig 1. Mean percent gabapentin-appropriate responding during two-lever discrimination training
for 30.0 mg/kg gabapentin versus vehicle. The ordinate axis indicates percent gabapentin-lever
responding. The abscissa indicates the number of training sessions for either gabapentin or
vehicle. Each session number represents both a gabapentin and vehicle training session. The
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number in parentheses indicates the number of rats that had not met criteria at that point in
training; the number of subjects was otherwise equal to N.
Gabapentin Time Course
Results from time course analysis generalization testing with gabapentin are shown in
Figure 3. Gabapentin produced full generalization at a 30.0 mg/kg dose 60 minutes after drug
administration. Gabapentin also produced partial generalization (75.95 [SEM = +/- 11.12%]
gabapentin-lever responding) at 30 minutes after drug administration. However, it was not
uncommon for gabapentin to produce ≥ 80% gabapentin-lever responding at 30 minutes post
drug administration during training sessions. A significant increase in response rates occurred 60
and 120 minutes after drug administration (F[6, 54] = 5.17, p < 0.001).
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Fig. 2. Generalization results for gabapentin time course analysis in rats trained to discriminate
30.0 mg/kg (N = 10) gabapentin from vehicle in a two-choice drug discrimination task. Mean
percent gabapentin-lever responding is shown in the upper panel, and mean responses per minute
(RPM) are shown in the lower panel. The dashed line at 80% indicates full generalization to the
gabapentin-lever. Prior to generalization testing, control tests were conducted with the
appropriate gabapentin training dose and vehicle. Rats with response rates below 5.0 RPM were
not included in the % gabapentin-lever data (the number of rats included is indicated in
parentheses). For generalization and response rate data, signiﬁcant differences (from 60 minutes
post injection in generalization testing; from vehicle in response rate) (calculated using Dunnett’s
multiple comparisons tests) are indicated by asterisks (*p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001).
Substitution Testing
Results for generalization testing with gabapentin are shown in Figure 2. Gabapentin
produced full substitution (≥ 80% gabapentin-lever responding) at the 30.0 mg/kg training dose
and at the 60.0 mg/kg and 120.0 mg/kg doses (ED50 = 8.15 mg/kg, 95% C.I. = 5.17-12.86
mg/kg). A significant increase in response rates (relative to vehicle) occurred at the 15.0 mg/kg,
30.0 mg/kg, 60.0 mg/kg, and 120.0 mg/kg doses (F[6, 54] = 6.27, p < 0.0001).
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Fig. 3. Generalization results for gabapentin in rats trained to discriminate 30.0 mg/kg (N = 10)
gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Ethanol
Results for generalization testing with ethanol are shown in Figure 4. Ethanol did not
substitute for the 30.0 mg/kg gabapentin training dose up to rate suppressant doses. However,
three of six rats displayed full substitution (95.24% gabapentin-lever responding) at the 1.5 g/kg
dose. A significant decrease in response rates (relative to vehicle) occurred at the 0.375 g/kg,
0.75 g/kg, 1.5 g/kg, and 3.0 g/kg doses (F[4, 36] = 15.76, p < 0.0001).
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Fig. 4. Generalization results for ethanol in rats trained to discriminate 30.0 mg/kg (N = 10)
gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (**p < 0.01; ****p < 0.0001). Note: the administration route for all
doses of ethanol was intragastric (oral gavage).
Pregabalin
Results for generalization testing with pregabalin are shown in Figure 5. Pregabalin
produced partial substitution at the 3.75 mg/kg (63.33 [SEM = +/- 13.90%] gabapentin-lever
responding), 7.5 mg/kg (79.45 +/- 11.09% gabapentin-lever responding), and 15.0 mg/kg (77.62
[SEM = +/- 12.68%] gabapentin-lever responding) doses. However, six of ten rats displayed full
substitution at the 3.75 g/kg dose, and seven of ten rats displayed full substitution at the 7.5
mg/kg and 15.0 mg/kg doses. A significant increase in response rate (relative to vehicle)
occurred at the 3.75 mg/kg, 7.5 mg/kg, and 15.0 mg/kg doses (F[4, 36) = 7.08, p < 0.001).
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Fig. 5. Generalization results for pregabalin in rats trained to discriminate 30.0 mg/kg (N = 10)
gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (*p < 0.05; **p < 0.01).
Carbamazepine
Results for generalization testing with carbamazepine are shown in Figure 6.
Carbamazepine produced partial substitution at the 40.0 mg/kg dose (62.50 [SEM = +/- 16.37%]
gabapentin-lever responding). A significant increase in response rate (relative to vehicle)
occurred at the 5.0 mg/kg, 10.0 mg/kg, and 20.0 mg/kg dose (F[4, 36) = 5.49, p = 0.0015). There
was no significant decrease in response rates at any dose tested, although the 40.0 mg/kg dose
produced rate disrupting effects in two of ten rats.
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Fig. 6. Generalization results for carbamazepine in rats trained to discriminate 30.0 mg/kg (N =
10) gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (*p < 0.05; **p < 0.01).
Pentobarbital
Results from generalization testing with pentobarbital are shown in Figure 7.
Pentobarbital produced partial substitution at the 1.25 mg/kg (76.44 [SEM = +/- 12.91%]
gabapentin-lever responding), 2.5 mg/kg (69.15 [SEM = +/- 14.90%] gabapentin-lever
responding), 5.0 mg/kg (70.59 [SEM = +/- 14.77%] gabapentin-lever responding), and 10.0
mg/kg (70.00 [SEM = +/- 14.84%] gabapentin-lever responding) doses. A significant increase in
response rate (relative to vehicle) occurred at the 1.25 mg/kg, 5.0 mg/kg, and 10.0 mg/kg doses.
A significant decrease in response rate (relative to vehicle) occurred at the 20.0 mg/kg dose (F[5,
45) = 21.03, p < 0.0001). Because of rate suppression at the 20.0 mg/kg pentobarbital dose, only
one of ten rats met the response rate criteria (≥ 5 RPM) to be included in the calculation for
percent gabapentin-lever responding. However, the rat displayed full substitution at the 20.0
mg/kg dose (ED50 = 1.67 mg/kg, 95% confidence interval (C.I.) = 0.80-3.50 mg/kg).
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Fig. 7. Generalization results for pentobarbital in rats trained to discriminate 30.0 mg/kg (N =
10) gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (*p < 0.05; **p < 0.01; ***p < 0.001).
Fentanyl
Results for generalization testing with fentanyl are shown in Figure 8. Fentanyl produced
strong partial substitution at the 0.02 mg/kg (73.93 [SEM = +/- 13.34%] gabapenting-lever
responding) and 0.04 mg/kg (75.92 [SEM = +/- 12.83%] gabapentin-lever responding) doses.
However, seven of nine rats displayed full substitution at the 0.02 mg/kg dose and seven out of
ten rats at the 0.04 mg/kg dose. A significant increase in response rate (relative to vehicle)
occurred at the 0.02 mg/kg and 0.04 mg/kg doses (F[4, 36) = 5.37, p = 0.0017). There was no
significant change in response rate relative to vehicle at any dose tested, although the 0.08 mg/kg
dose produced rate disrupting effects in three of ten rats.
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Fig. 8. Generalization results for fentanyl in rats trained to discriminate 30.0 mg/kg (N = 10)
gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (*p < 0.05).
Buspirone
Results for generalization testing with buspirone are shown in Figure 9. Because of the
rate suppression at the 3.0 mg/kg buspirone dose, only three of ten rats met the response rate
criteria (≥ 5 RPM) to be included in the calculation for percent gabapentin-lever responding.
However, those three rats displayed partial substitution for 30.0 mg/kg gabapentin (68.42 [SEM
= +/- 17.30%] gabapentin-lever responding) at the 3.0 mg/kg dose. A significant decrease in
response rate (relative to vehicle) occurred at the 3.0 mg/kg dose (F[4, 36] = 10.74, p < 0.0001).
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Fig. 9. Generalization results for buspirone in rats trained to discriminate 30.0 mg/kg (N = 10)
gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (**p < 0.01).
Amphetamine
Results for generalization testing with amphetamine are shown in Figure 10.
Amphetamine did not substitute for the 30.0 mg/kg gbapentin training dose at any of the doses
tests. However, the 0.25 mg/kg dose amphetamine fully substituted in five of ten rats. There was
no significant change in response rate relative to vehicle at any dose tested, although the 2.0
mg/kg dose produced rate disrupting effects in two of ten rats.
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Fig. 10. Generalization results for amphetamine in rats trained to discriminate 30.0 mg/kg (N =
10) gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks.
Raclopride
Results for generalization testing with raclopride are shown in Figure 11. Raclopride did
not substitute for 30.0 mg/kg gabapentin at any of the tested doses. A significant increase in
response rates occurred at the 0.05 mg/kg dose, and a significant decrease occurred at the 0.4
mg/kg dose (F[5, 45] = 10.90, p < 0.0001).
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Fig. 12. Generalization results for raclopride in rats trained to discriminate 30.0 mg/kg (N = 10)
gabapentin from vehicle in a two-choice drug discrimination task. Mean percent gabapentinlever responding is shown in the upper panel, and mean responses per minute (RPM) are shown
in the lower panel. The dashed line at 80% indicates full generalization to the gabapentin-lever.
Prior to generalization testing, control tests were conducted with the appropriate gabapentin
training dose and vehicle. Rats with response rates below 5.0 RPM were not included in the %
gabapentin-lever data (the number of rats included is indicated in parentheses). For response rate
data, signiﬁcant differences from vehicle (calculated using Dunnett’s multiple comparisons tests)
are indicated by asterisks (*p < 0.05; **p < 0.01).
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DISCUSSION
Gabapentin 30.0 mg/kg (i.p.) was successfully established as a discriminative cue in all
10 rats. Furthermore, gabapentin fully generalized (≥ 80% gabapentin-lever responding) during
dose-response testing for itself. The barbiturate pentobarbital (20.0 mg/kg) produced full
substitution. Pregabalin (7.5 and 15.0 mg/kg doses), carbamazepine (40.0 mg/kg dose), fentanyl
(0.02 and 0.04 mg/kg), and buspirone (3.0 mg/kg) all produced partial substitution (≥ 60%
gabapentin-lever responding) for gabapentin. Ethanol and raclopride did not substitute for
gabapentin. The psychostimulant amphetamine also did not produce substitution; however, the
0.25 mg/kg dose D-amphetamine fully substituted in five of ten rats. Based on these findings,
gabapentin appears to produce subjective effects similar to those exerted by many of the
GABAergic compounds tested in this study.
Gabapentin
Although several studies have used the anticonvulsant gabapentin as a test compound in
drug discrimination studies, the present study is the first to demonstrate that gabapentin can be
established as a discriminative cue. Of the initial 10 animals obtained for this study, all 10 of
these subjects passed the two-lever discrimination criteria and were able to discriminate
gabapentin 30.0 mg/kg dose from vehicle. In a similar drug discrimination study where the
anticonvulsant tiagabine (acts by inhibiting reuptake at GABA GAT-1) was used as a training
compound, only 25 of 40 rats were successful in discriminating 30.0 mg/kg tiagabine from
vehicle (McDonald et al., 2008). These findings show that not all drugs are capable of being
readily established as a discriminative cue and suggest the ability of gabapentin to produce
robust subjective effects.
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Gabapentin produced full generalization at the 30.0 mg/kg dose 60 minutes after drug
administration. Gabapentin also produced partial substitution at 30 minutes after drug
administration; however, 8 of 10 rats displayed full substitution at this time point. Although it is
typical to test 60 minutes after the administration of gabapentin (Radulovic et al., 1995), time
course analysis of drug effects revealed that it was not uncommon for gabapentin to produce ≥
80% gabapentin-lever responding at 30 minutes post drug administration during training
sessions. Additionally, a Dunnett’s multiple comparisons test revealed no significant difference
between gabapentin generalization at 30 and 60 minutes post injection. Coinciding with previous
literature, gabapentin has been shown to have no effect on locomotor activity at 30 and 60
minutes post injection (Tanabe et al., 2005). In this study, a significant increase in response rates
occurred 120 minutes after drug administration.
Ethanol
The CNS depressant ethanol did not produce substitution for gabapentin in the present
study, as gabapentin-appropriate responses were below the substitution threshold (i.e., < 60%
gabapentin-lever responding). However, three of six rats displayed full substitution at the 1.5
g/kg ethanol dose. Additionally, a significant decrease in response rates (relative to vehicle)
occurred at all doses leading up to the 3.0 g/kg dose, which precluded tested higher doses of
ethanol. In a previous study by Besheer, Frisbee, Randall, Jaramillo, & Masciello (2016),
gabapentin (120.0 mg/kg) displayed partial substitution (defined as >40% ethanol-lever
responding in Besheer’s study) as a test compound in rats trained to discriminate ethanol 1.0 g/kg
(training dose) from vehicle. However, this may be due to the test dose (120.0 mg/kg gabapentin)
being larger than the training dose (30.0 mg/kg gabapentin) used in this study. Gabapentin’s
involvement with the production of subjective drug effects likely involves indirect modulation of
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GABAergic pathways or through inhibition of voltage-gated Ca2+ channels. Although ethanol
and gabapentin both inhibit L-type voltage-gated Ca2+ channels, ethanol’s interaction with these
channels produce non-reinforcing objective effects (i.e., increase in urination, lower blood
pressure, increased aggression) (Walter & Messing, 1999). The reinforcing effects of ethanol are
more likely thought to involve ethanol’s indirect modulation of neurotransmitters in the nucleus
accumbens (i.e., GABAA, 5-HT, and endocannabinoid modulation) (Harris et al., 1997;
Yoshimoto et al., 1992; Hungund et al., 2003), which may explain ethanol’s lack of substitution
with gabapentin. Additionally, ethanol is known to produce a complex discriminative cue,
composed of distinct components that are mediated by different neurotransmitter systems (Grant,
1999). As such, multiple features of the complex cue could serve as the discriminative basis for
the drug’s effect (Grant, 1999). Thus, it is difficult to draw conclusions between the subjective
effects of gabapentin and ethanol without knowing the discriminative basis for ethanol’s cue in a
particular animal.
Pregabalin
In the present study, the anticonvulsant and analgesic pregabalin produced partial
substitution at the 7.5 mg/kg and 15.0 mg/kg doses, with many of the subjects emitting full
generalized responding. Pregabalin shares a novel mechanism of action with gabapentin, binding
selectively to the α2δ subunit of voltage-gated Ca2+ channels, ultimately reducing excitatory
neurotransmitter release. A thorough dose-response spectrum of pregabalin (i.e., increase dose
until stimulus generalization or rate disrupting effects occur) should be further explored in order
to conclude the potency of pregabalin in relation to the training drug (30.0 mg/kg gabapentin).
Higher doses of pregabalin would be expected to produce full substitution relative to gabapentin.
Carbamazepine
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Generalization testing with the anticonvulsant carbamazepine produced partial
substitution at the 40.0 mg/kg dose. A significant increase in response rate (relative to vehicle)
occurred at the 10.0 mg/kg dose. There was no significant decrease in response rates at any dose
tested, although the 40.0 mg/kg dose produced rate disrupting effects in two of ten rats. The
range in which carbamazepine and gabapentin exert their pain attenuating effects
(carbamazepine: ED50 = 42.2 mg/kg; gabapentin 50.0 mg/kg) (De Vry, Kuhl, Franken-Kunkel, &
Eckel, 2004) relate closely to the doses that produced substitution in this study. Carbamazepine
is thought to act through the blockade of Na+ channels (Rogawski, Loescher, & Rho, 2016;
MacDonald, 1995; Czapinski, Blaszczyk, & Czuczwar, 2005) and, more recently, Nav1.8-like
sodium channels (Cardenas et al., 2006). However, it has been hypothesized that, similar to the
proposed mechanisms of gabapentin, carbamazepine is able to modulate K+ currents and
GABAergic pathways (Olpe, Kolb, Hausdorf, & Haas, 1991; Waldmeier et al., 1995). This
hypothesis would serve to explain the analogous antiallodynic effects of each drug within a
similar dose range.
Pentobarbital
In this study, the barbiturate pentobarbital produced partial substitution at the 1.25 mg/kg,
2.5 mg/kg, 5.0 mg/kg, and 10.0 mg/kg doses. Because of rate suppression at the 20.0 mg/kg
pentobarbital dose, only one of ten rats met the response rate criteria (≥ 5 RPM) to be included in
the calculation for percent gabapentin-lever responding. However, that rat displayed full
substitution at the 20.0 mg/kg dose. Although not yet replicated in a rodent model, previous
studies have shown the ability of gabapentin to produce significant increases in GABA
concentrations in human neocortical slices (Errante, Williamson, Spencer, & Petroff, 2002),
similar to the GABAA agonism of pentobarbital. Gabapentin may modulate GABA concentration
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by inhibiting GABA transaminase inhibitor (GABA-T; responsible for GABA degradation) or by
modulating non-vesicular GABA release via GAT-1 (GABA transporter) (Loscher, Honack, &
Taylor, 1991; Sills, 2006; Goldlust et al., 1995; Leach et al., 1997). Additionally, the
anticonvulsant properties of gabapentin and pentobarbital (Akula, Dhir, & Kulkarni, 2009) may
be produced by the shared mechanism of inhibiting voltage-gated Ca2+ channels (Werz &
Macdonald, 1982; Barker & Rogawski, 1993; Schoeber, Sokolova, & Gingrich, 2010). These
shared interactions may serve to explain the shared discriminative and therapeutic effects of
pentobarbital and gabapentin.
Fentanyl
In this study, the opioid fentanyl produced partial substitution at the 0.02 mg/kg and 0.04
mg/kg doses. There was no significant change in response rate relative to vehicle at any dose
tested, although the 0.08 mg/kg dose produced rate-disrupting effects in three of ten rats.
Fentanyl and gabapentin have been shown to share both antiallodynic and antihyperalgesic
properties (Rode et al., 2007; Celerier et al., 2000). The doses used to produce these
antinociceptive effects in previous studies (50.0-100.0 mg/kg gabapentin and 0.01-0.04 mg/kg
fentanyl) closely resemble the range of doses tested in this study that produced generalizable
subjective effects (30.0 mg/kg gabapentin training dose; 0.02-0.04 mg/kg fentanyl).
Additionally, gabapentin-like compounds have been shown to block morphine-induced
dopamine release in the nucleus accumbens (responsible for reinforcing drug effects), as well as
reverse morphine-induced place preference in rodent models (Andrews et al., 2001). Based on
these findings and gabapentin’s known modulation of opioid-induced behavioral effects,
gabapentin likely produces GABAergic effects similar to those elicited from μ opioid activation.
Buspirone
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Because of the rate suppression at the 3.0 mg/kg buspirone dose, only three of ten rats
met the response rate criteria (≥ 5 RPM) to be included in the calculation for percent gabapentinlever responding. However, those three rats displayed partial substitution for gabapentin at the
3.0 mg/kg dose. A significant decrease in response rate (relative to vehicle) occurred at the 3.0
mg/kg dose. Although gabapentin does not modulate serotonin reuptake or concentration
(Southam et al., 1998), previous studies have shown gabapentin and buspirone to share a similar
profile, both producing significant anxiolytic-like effects within a similar dose range (30.0 mg/kg
gabapentin; 5.0 mg/kg buspirone, s.c.) (Singh et al., 1996; Davis, Cassella, & Kehne, 1988).
Additionally, studies assessing the anxiolytic effects of buspirone in a fear-potentiated startle
paradigm have demonstrated that buspirone likely does not exert its behavioral effects through 5HT1A agonism (Davis, Cassella, & Kehne, 1988), but rather through antagonism of the dopamine
D2 receptor (Kamien & Woolverton, 1990; Ceretta et al. 2016; Ceretta et al. 2018). Thus,
gabapentin and buspirone may act of similar mechanisms to exert their anxiolytic behavioral
effects.
Amphetamine
In this study, the psychostimulant amphetamine did not substitute for gabapentin.
However, the 0.25 mg/kg dose amphetamine fully substituted in five of ten rats. There was no
significant change in response rate relative to vehicle at any dose tested, although the 2.0 mg/kg
dose produced rate disrupting effects in two of ten rats. Gabapentin has been shown to produce
counteractive effects to amphetamine (dopamine releaser), preventing hyperlocomotion, memory
deficit, and social isolation is in rodent models of schizophrenia (Ceretta et al., 2016). Similarly,
gabapentin has also been shown the reduce orofacial movements (animal model of tardive
dyskinesia, a common adverse effect of chronic antipsychotic medication), induced by the D2
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antagonist haloperidol, and restore locomotor function in mice (Ceretta et al. 2018). However,
the mechanisms by which gabapentin exerts its counteractive effects remain unclear, as
gabapentin does not produce changes tyrosine hydroxylase (a dopaminergic marker) or
monoamine levels in the striatum in mice (Ceretta et al. 2018). In this study, the lowest dose of
amphetamine (0.25 mg/kg) produced full substitution of five of ten rats. In future studies, doses
lower than 0.25 mg/kg should be tested for gabapentin substitution.
Raclopride
In this study, the D2 antagonist raclopride did not produce substitution at any of the tested
doses. A significant increase in response rates occurred at the 0.05 mg/kg dose, and a significant
decrease occurred at the 0.4 mg/kg dose. Due to raclopride’s high binding specificity to the
dopamine D2 receptor, the compound not been shown to produce substitution in drug
discrimination paradigms that use a non-dopaminergic modulating compound as a discriminative
cue. Based on the findings in this study, gabapentin does not generalize with raclopride, and
therefore, does not likely modulate dopamine D2 receptors.
Limitations
Several limitations exist that should be considered when drawing conclusions from this
study. Although drug discrimination serves as a useful tool for deducing subjective drug effects,
and pharmacological similarities can be surmised through stimulus generalization, this paradigm
does not fully explain the mechanism by which gabapentin exerts its modulatory drug effects.
Additionally, gabapentin may produce a complex discriminative cue, composed of multiple cues
mediated by different neurotransmitter systems. In this case, test compounds that produce effects
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similar to a single component of the compound cue may substitute for gabapentin while not
emulating the full mechanism of gabapentin.
Directions for Future Research
Future research should attend to elucidate the mechanism by which gabapentin exerts its
subjective effects. This may be achieved through the exploration of gabapentin’s interaction with
GABAergic, opioid, and dopaminergic neurotransmitter systems at the cellular level. Further
elucidation of these interactions is critically important for fully explaining and predicting the
subjective effects and drug interactions. Additionally, this would help explain the witnessed
abuse potential of gabapentin, especially in combination with other prescription and illicit drugs.
Conclusion
Gabapentin, a synthetic analog of the neurotransmitter gamma-Aminobutyric acid
(GABA), is an anticonvulsant primarily used for the treatment of epileptic seizures and
neuropathic pain, as well as narcotic withdrawal and detoxification. Gabapentin’s suspected
mechanism of action involves interaction with the α2δ-1 subunit of voltage gated Ca 2+ channels,
ultimately reducing the release of excitatory neurotransmitters. Although the exact action of
gabapentin remains somewhat unclear, there is increasing evidence that the drug possesses
considerable abuse potential. Thus, there is much to learn about the pharmacological actions of
gabapentin.
The present study presented evidence that rats can be successfully trained to discriminate
30.0 mg/kg gabapentin from vehicle in a two-lever drug discrimination task. Gabapentin
produced full substitution (≥ 80% gabapentin-lever responding) for itself at 30.0 mg/kg (training
dose), 60.0 mg/kg, and 120.0 mg/kg doses. The present study also supported conclusions from
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previous studies that gabapentin exert its subjective effects either directly or indirectly through
GABAergic pathways. Additionally, gabapentin’s effect on GABAergic pathways may modulate
other neurotransmitter pathways within the brain. The identification of pharmacological
mechanisms that mediate the discriminative stimulus properties of gabapentin is important both
to understand the stimulus properties responsible for stimulus generalization to drugs which exert
positive subjective effects and to improve the ability of drug discrimination models to identify
new compounds with abuse potential. New gabapentinoid compounds have been developed with
a higher binding affinity to known receptors and a more liberal receptor pharmacology,
suggesting greater abuse potential with the use of these compounds. For example, the relatively
new gabapentinoid and anticonvulsant compound pregabalin has a greater binding affinity at the
α2δ-1 subunit of voltage-gated Ca2+ channels. Pregabalin also partially substituted for gabapentin
at much lower relative doses than the 30.0 mg/kg training dose.
Many of the compounds that produced substitution in this study are controlled substances
that produce rewarding subjective effects through GABAergic. However, gabapentin has been
shown to inhibit neuronal firing in the substantia nigra (Bloms-Funke & Loscher, 1996), inhibit
dopamine and monoamine release of stimulated neurons (Pugsley, Whetzel, & Dooley, 1998),
and block or reduce the reinforcing effects of opioids (Pugsley, Whetzel, & Dooley, 1998).
Although compounds that serve to increase GABA concentrations have been shown to produce
their reinforcing effects through interaction with the posterior ventral tegmental area (McBride,
Murphy, & Ikemoto, 1999; Ikemoto, Murphy, & McBride, 1998; Ikemoto, Murphy, McBride,
1997), this effect on reinforcement is thought to be facilitatory (Bossert & Franklin, 2003;
Seeger, Carlson, & Nazzaro, 1981). Studies suggest that reinforcement of GABAergic
compounds may be mediated by opioid and dopaminergic mechanisms (Bossert & Franklin,
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2001; Bossert & Franklin, 2003; Seeger, Carlson, & Nazzaro, 1981), which would explain the
substitution of similar compounds to gabapentin.
The substitution demonstrated in this study is supported by reports of recreational or selfmedicating poly-drug misuse, indicating the ability of gabapentin to modulate pathways involved
in producing positive subjective effects. Similarly, because gabapentin is used to treat opioid,
benzodiazepine, and alcohol detoxification and withdrawal, it is important for clinicians to
monitor drug-seeking behaviors. Thus, the mechanisms of action surrounding gabapentin
require further exploration, and the pharmacological modulatory effects of gabapentin should be
considered by clinicians and researchers alike when working with the drug.
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APPENDIX A

Order of drug testing for each animal
Animal
1
2
3
4
5
6
7
8
9
10

GTC
GTC
GTC
GTC
GTC
GTC
GTC
GTC
GTC
GTC

AMP
GPN
GPN
AMP
GPN
AMP
GPN
PNT
GPN
PNT

BUS
AMP
PGB
PNT
BUS
PNT
AMP
PGB
AMP
ETH

PGB
BUS
PNT
BUS
PNT
GPN
PNT
ETH
BUS
GPN

ETH
PBG
ETH
PGB
AMP
BUS
BUS
GPN
PNT
RAC

GPN
ETH
BUS
GPN
PGB
PGB
PGB
RAC
PGB
AMP

RAC
RAC
AMP
ETH
ETH
ETH
ETH
AMP
ETH
CBZ

PNT
PNT
CBZ
RAC
RAC
RAC
RAC
CBZ
RAC
FTN

CBZ
CBZ
FTN
CBZ
CBZ
CBZ
CBZ
FTN
CBZ
BUS

FTN
FTN
RAC
FTN
FTN
FTN
FTN
BUS
FTN
PGB

GTC = gabapentin time course, GPN = gabapentin, AMP = amphetamine, BUS = buspirone,
PGB = pregabalin, ETH = ethanol, RAC = raclopride, PNT = pentobarbital, CBZ =
carbamazepine, FTN = fentanyl
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Substitution testing results for each animal

Ethanol

Pregabalin

Carbamazepine

Pentobarbital

Fentanyl

Buspirone

Amphetamine

Raclopride

Gabapentin

Dose
(mg/kg)
375
750
1500
3000
1.875
3.75
7.5
15.0
5.0
10.0
20.0
40.0
1.25
2.5
5.0
10.0
20.0
0.01
0.02
0.04
0.08
0.375
0.75
1.5
3.0
0.25
0.5
1.0
2.0
0.025
0.05
0.1
0.2
0.4
3.75
7.5
15.0
30.0
60.0

No Substitution
1, 2, 3, 4, 5, 7, 8, 9, 10
2, 3, 4, 5, 6, 7, 9
3, 4, 8, 9
4, 8, 9
1, 2, 4, 9, 10
1, 3, 4, 9
1, 5, 9
5, 8
1, 4, 6, 7, 8, 10
3, 4, 5, 8, 9, 10
4, 5, 6, 8, 9, 10
5, 8, 10
1, 5
2, 9, 10
2, 3, 5
3, 8, 10
2, 4, 5, 6, 9, 10
3, 9
5, 10
1, 6, 8, 9
1, 2, 5, 8, 9, 10
1, 3, 4, 6, 7, 8, 10
1, 3, 4, 9, 10
9
1, 2, 4, 8, 10
1, 2, 3, 4, 6, 8, 9, 10
1, 3, 4, 5, 6, 8, 9, 10
1, 3, 4, 6, 8, 9, 10
2, 3, 4, 6, 7, 8, 9, 10
1, 2, 3, 5, 6, 7, 9, 10
2, 3, 4, 6, 7, 8
2, 4, 6, 8, 9, 10
8, 9, 10
1, 2, 5, 7, 8, 9, 10
1, 2, 7, 8, 10
1, 2, 4, 8, 9, 10
10
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Partial

2
8

4

8

2
3
2
8

2

Full
6
8
2, 5, 6
6
3, 5, 6, 7
2, 5, 6, 7, 8, 10
2, 3, 4, 6, 7, 8, 10
1, 2, 3, 6, 7, 9, 10
2, 3, 5, 9
1, 2, 6, 7
1, 2, 3, 7
1, 3, 4, 6, 9
2, 3, 4, 6, 7, 9, 10
1, 3, 4, 5, 6, 7, 8
1, 4, 6, 7, 8, 9, 10
1, 2, 4, 5, 6, 7, 9
9
1, 3, 7, 8
1, 2, 4, 5, 6, 7, 8
1, 3, 4, 6, 7, 8, 9
5, 7
3, 4, 6, 7
5, 9
5, 6
5, 6
3, 5, 6, 7, 9
5, 7
2, 7
5
1, 5
4, 8
1, 5, 9, 10
1, 3, 5, 7
5, 6
3, 4, 6
3, 4, 5, 6, 9
3, 5, 6, 7
1, 2, 3, 4, 5, 6, 7, 8, 9, 10
1, 2, 3, 4, 5, 6, 7, 8, 9

120.0

2, 5
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1, 3, 4, 6, 7, 8, 9, 10

APPENDIX B

Institutional Animal Care and Use Committee approval form
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